Comment
doi: 10.1136/annrheumdis-2020-218693.
Epub 2020 Sep 1.
Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al
Affiliations
- PMID: 32873553
- DOI: 10.1136/annrheumdis-2020-218693
Item in Clipboard
Comment
Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al
Ann Rheum Dis.
2022 Oct.
No abstract available
Keywords: immune system diseases; inflammation; interleukin 1 receptor antagonist protein.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al' by Buckley.Ann Rheum Dis. 2022 Oct;81(10):e195. doi: 10.1136/annrheumdis-2020-218715. Epub 2020 Sep 1. Ann Rheum Dis. 2022. PMID: 32873552 No abstract available.
Comment on
-
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218243. Epub 2020 Jul 9. Ann Rheum Dis. 2021. PMID: 32647027 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
